Buying Undervalued Commercial Biotechs: Geron Example

Anna asks for other names; Jonathan explains why he bought Geron—valuation near enterprise-value multiples, approved drug potential, and upcoming readouts.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app